OBJECTIVE: To review the effect of interventions, including a complete restriction in the use of fluoroquinolones (FQs), used to control an outbreak of hospital-onset Clostridium difficile infection (HO-CDI) caused primarily by the epidemic North American pulsed-field gel electrophoresis type 1 strain. DESIGN: Retrospective cohort and case-control study of all episodes of HO-CDI both before and after 2 interventions. SETTING: Community hospital; January 1, 2005, through March 31, 2007. Interventions. Complete, 5-month, facility-wide restriction of fluoroquinolone use, during which a change in the environmental-services contractor occurred. RESULTS: During a 27-month period, 319 episodes of HO-CDI occurred. The hospital-wide mean defined daily doses of antimicrobials decreased 22% after restricting FQ use, primarily because of a 66% decrease in the use of FQs. The interventions were also associated with a significant change in the HO-CDI incidence trends and with an absolute decrease of 22% in HO-CDI cases caused by the epidemic strain (from 66% before the intervention period to 44% during and after the intervention period; P=.02). Univariate analysis revealed that case patients with HO-CDI due to the epidemic strain were more likely than control patients, who did not have diarrhea, to receive a FQ, whereas case patients with HO-CDI due to a nonepidemic strain were not. However, FQ use was not significantly associated with HO-CDI in multivariable analysis. CONCLUSIONS: An outbreak of epidemic-strain HO-CDI was controlled at a community hospital after an overall decrease in antimicrobial use, primarily because of a restriction of FQ use and a change in environmental-services contractors. The restriction of FQ use may be useful as an adjunct control measure in a healthcare facilities during outbreaks of epidemic-strain HO-CDI.
OBJECTIVE: To review the effect of interventions, including a complete restriction in the use of fluoroquinolones (FQs), used to control an outbreak of hospital-onset Clostridium difficile infection (HO-CDI) caused primarily by the epidemic North American pulsed-field gel electrophoresis type 1 strain. DESIGN: Retrospective cohort and case-control study of all episodes of HO-CDI both before and after 2 interventions. SETTING: Community hospital; January 1, 2005, through March 31, 2007. Interventions. Complete, 5-month, facility-wide restriction of fluoroquinolone use, during which a change in the environmental-services contractor occurred. RESULTS: During a 27-month period, 319 episodes of HO-CDI occurred. The hospital-wide mean defined daily doses of antimicrobials decreased 22% after restricting FQ use, primarily because of a 66% decrease in the use of FQs. The interventions were also associated with a significant change in the HO-CDI incidence trends and with an absolute decrease of 22% in HO-CDI cases caused by the epidemic strain (from 66% before the intervention period to 44% during and after the intervention period; P=.02). Univariate analysis revealed that case patients with HO-CDI due to the epidemic strain were more likely than control patients, who did not have diarrhea, to receive a FQ, whereas case patients with HO-CDI due to a nonepidemic strain were not. However, FQ use was not significantly associated with HO-CDI in multivariable analysis. CONCLUSIONS: An outbreak of epidemic-strain HO-CDI was controlled at a community hospital after an overall decrease in antimicrobial use, primarily because of a restriction of FQ use and a change in environmental-services contractors. The restriction of FQ use may be useful as an adjunct control measure in a healthcare facilities during outbreaks of epidemic-strain HO-CDI.
Authors: Krishna Rao; Dejan Micic; Mukil Natarajan; Spencer Winters; Mark J Kiel; Seth T Walk; Kavitha Santhosh; Jill A Mogle; Andrzej T Galecki; William LeBar; Peter D R Higgins; Vincent B Young; David M Aronoff Journal: Clin Infect Dis Date: 2015-03-31 Impact factor: 9.079
Authors: Tamar F Barlam; Sara E Cosgrove; Lilian M Abbo; Conan MacDougall; Audrey N Schuetz; Edward J Septimus; Arjun Srinivasan; Timothy H Dellit; Yngve T Falck-Ytter; Neil O Fishman; Cindy W Hamilton; Timothy C Jenkins; Pamela A Lipsett; Preeti N Malani; Larissa S May; Gregory J Moran; Melinda M Neuhauser; Jason G Newland; Christopher A Ohl; Matthew H Samore; Susan K Seo; Kavita K Trivedi Journal: Clin Infect Dis Date: 2016-04-13 Impact factor: 9.079
Authors: K de With; F Allerberger; S Amann; P Apfalter; H-R Brodt; T Eckmanns; M Fellhauer; H K Geiss; O Janata; R Krause; S Lemmen; E Meyer; H Mittermayer; U Porsche; E Presterl; S Reuter; B Sinha; R Strauß; A Wechsler-Fördös; C Wenisch; W V Kern Journal: Infection Date: 2016-06 Impact factor: 3.553
Authors: Isaac See; Yi Mu; Jessica Cohen; Zintars G Beldavs; Lisa G Winston; Ghinwa Dumyati; Stacy Holzbauer; John Dunn; Monica M Farley; Carol Lyons; Helen Johnston; Erin Phipps; Rebecca Perlmutter; Lydia Anderson; Dale N Gerding; Fernanda C Lessa Journal: Clin Infect Dis Date: 2014-03-05 Impact factor: 9.079
Authors: T C Jenkins; S A Stella; L Cervantes; B C Knepper; A L Sabel; C S Price; L Shockley; M E Hanley; P S Mehler; W J Burman Journal: Infection Date: 2012-11-17 Impact factor: 3.553
Authors: J Freeman; M P Bauer; S D Baines; J Corver; W N Fawley; B Goorhuis; E J Kuijper; M H Wilcox Journal: Clin Microbiol Rev Date: 2010-07 Impact factor: 26.132
Authors: Fred C Tenover; Susan Novak-Weekley; Christopher W Woods; Lance R Peterson; Thomas Davis; Paul Schreckenberger; Ferric C Fang; Andre Dascal; Dale N Gerding; Jim H Nomura; Richard V Goering; Thomas Akerlund; Alice S Weissfeld; Ellen Jo Baron; Edith Wong; Elizabeth M Marlowe; Joseph Whitmore; David H Persing Journal: J Clin Microbiol Date: 2010-08-11 Impact factor: 5.948